AstraZeneca PLC (LON:AZN)
13,982
+52 (0.37%)
Nov 13, 2026, 4:37 PM GMT
AstraZeneca Employees
AstraZeneca had 96,100 employees as of December 31, 2025. The number of employees increased by 1,800 or 1.91% compared to the previous year. That makes AstraZeneca the 317th largest employer in the world and 9th in the United Kingdom.
Employees
96,100
Change (1Y)
1,800
Growth (1Y)
1.91%
Revenue / Employee
488.96K GBP
Profits / Employee
86.45K GBP
Market Cap
216.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96,100 | 1,800 | 1.91% |
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 17,000 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 9,000 |
| Genus | 2,921 |
AstraZeneca News
- 6 hours ago - AZN : FDA Okays IMFINZI Combination Regimen For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 8 hours ago - AstraZeneca announces FDA approval of imfinzi/EV combination - TheFly
- 8 hours ago - Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer - Business Wire
- 12 hours ago - AstraZeneca’s Alexion receives FDA approval for Klygefa - TheFly
- 13 hours ago - FDA approves AstraZeneca combo treatment for bladder cancer - TheFly
- 14 hours ago - AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports - Reuters
- 15 hours ago - AstraZeneca cuts 600 sales jobs in U.S., Bloomberg reports - TheFly
- 18 hours ago - EU panel backs AstraZeneca hypertension drug baxdrostat - Reuters